ch.oddb.org
 
Apotheken | Hôpital | Interactions | LiMA | Médecin | Médicaments | Services | T. de l'Autorisation
Information professionnelle sur Warix® 0,5%:Drossapharm AG
Information professionnelle complèteDDDimprimé 
Composit.Forme gal.Indic./emploiPosolog./mode d'empl.Contre-Ind.PrécautionsInteract.Grossesse
Apt.conduiteEffets indésir.SurdosagePropriétésPharm.cinét.Donn.précl.RemarquesNum. Swissmedic
TitulaireMise à jour 
D06BB04 - PodophyllotoxinATC-DDD Version 2016. Source: WHO
D - Dermatologicals

Most of the drugs in this group are preparations for topical use. Some few preparations for systemic use with clear dermatological applications, e.g. griseofulvin (antimycotic), retinoids (for treatment of acne) and psoralens and retinoids (for treatment of psoriasis) are classified in this group.

Only oral preparations in ATC group D are given DDDs. Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease. Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.

D06 - Antibiotics and Chemotherapeutics for Dermatological Use

This group comprises products for topical use in skin infections etc.
Antimicrobial chemotherapeutics are classified here, while antineoplastic chemotherapeutics are classified in L01.

D06B - Chemotherapeutics for Topical Use

This group includes antimicrobial chemotherapeutics for dermatological use, except:
Combinations with antibiotics - D06C
Combinations with corticosteroids - D07C
Antineoplastic chemotherapeutics are classified in L01 - Antineoplastic agents.

D06BB - Antivirals

This group includes both direct acting antivirals and other agents for viral diseases.
Mucoadhesive formulations of aciclovir are classified in J05AB01.
Podophyllin preparations are classified at the 5th level for podophyllotoxin.

D06BB04 - Podophyllotoxin
2024 ©ywesee GmbH
Einstellungen | Aide | FAQ | Identification | Contact | Home